NORDIC NANOVECTOR ANNOUNCES RESIGNATION OF CHIEF MEDICAL OFFICER
Oslo, Norway, 13 November 2015
Nordic Nanovector ASA (OSE: NANO), a company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology, announces that its Chief Medical Officer, Cristina Oliva, MD, has resigned and will leave Nordic Nanovector as per end of January 2016 to pursue other career opportunities in the UK, where she resides with her family.
The Company has initiated a search for a new CMO and, until a suitable full-time successor is announced, has engaged the services of a qualified medical oncologist, trained in the US and specialised in the treatment of lymphomas, as its Medical Signatory. In addition, the clinical leadership team will continue to lead the clinical development activities with support from Nordic Nanovector’s executive team.
“We regret Cristina’s departure but respect her decision,” says Luigi Costa, CEO of Nordic Nanovector ASA: “Cristina has made a substantial contribution to the success of the company and is a respected expert among colleagues, our board and investors. We wish her the best of luck.”
“It has been a very exciting time and I am sad to be leaving the company at this stage in its development. But I will follow its path and progress closely,” says Cristina Oliva. “I am convinced that the lead product Betalutin® will be a success and it has been a privilege working with the company’s diverse, dedicated and exceptionally competent team.”
For further information, please contact:
Luigi Costa, Chief Executive Officer
Cell: +41 79 124 8601
International Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44 207 282 2948/+44 207 282 2949
About Nordic Nanovector
Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018.
Betalutin® comprises a tumour-seeking anti-CD37 antibody (HH1) conjugated to a low intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019.
Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications.
Further information about the Company can be found at www.nordicnanovector.com